Literature DB >> 11180174

Distribution of fibronectin isoforms in human renal disease.

A Van Vliet1, H J Baelde, L J Vleming, E de Heer, J A Bruijn.   

Abstract

Fibronectin (FN) is an extracellular matrix component which appears in different isoforms, due to alternative mRNA splicing of the ED-A, ED-B, and IIICS regions, and subsequent post-translational modifications. The FN isoforms, some of which occur specifically during fetal development and in fibrogenic diseases, have been reported to play a role in various biological functions, such as regulation of the matrix assembly, adhesion, and proliferation. The contribution of these FN isoforms to the pathogenesis of chronic renal diseases, which are also fibrogenic disorders, is not well known. This study therefore examined the distribution of FN isoforms in renal diseases by immunohistochemistry, with a panel of isoform-specific monoclonal antibodies (MAbs), applied to 63 abnormal renal biopsies and ten normal controls. Normal kidneys contained total FN (MAb IST4) both in the mesangial and in the interstitial extracellular matrix (ECM), but only traces of ED-A-positive FN (MAb IST9), and no ED-B-positive FN (MAb BC1) or oncofetal FN (MAb FDC6) was found in normal renal tissue. All patients with renal disease demonstrated increased total FN staining of the interstitium and the mesangium. Periglomerular fibrotic lesions and fibrous crescents showed massive accumulation of total FN, whereas the amount of total FN in the ECM of obsolescent glomeruli was decreased, compared with that in normal mesangial ECM. Oncofetal (FDC6), EDB-negative (MAb IST6), ED-A-positive, and ED-B-positive FN isoforms were found in glomerular ECM accumulations and in fibrous crescents. Tubulointerstitial fibrotic lesions predominantly contained the ED-A-positive FN isoform, whereas in globally sclerotic glomeruli, predominantly ED-B-positive FN was observed. The expression of FN isoforms was similar in all renal diseases studied. These results show that in various renal diseases, oncofetal (FDC6) FN and ED-A- and ED-B-positive isoforms of FN accumulate at locations of chronic lesions, independently of the aetiology of the disease. The deposition of these isoforms in human renal tissue may play a role in the modulation of the immune response by attracting monocytes and lymphocytes to the injured kidney. Furthermore, because the ED-B-positive FN isoform is highly susceptible to proteolytic degradation, its accumulation may play a role in scar formation and tissue repair. ED-B-positive FN forms a temporary scaffold supporting the cells, which can easily be cleared by proteolytic degradation once new tissue has been produced at the site of injury.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11180174     DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH783>3.0.CO;2-P

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  25 in total

Review 1.  Fibronectin: functional character and role in alcoholic liver disease.

Authors:  Razia S Aziz-Seible; Carol A Casey
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Extracellular Matrix in Kidney Fibrosis: More Than Just a Scaffold.

Authors:  Roman David Bülow; Peter Boor
Journal:  J Histochem Cytochem       Date:  2019-05-22       Impact factor: 2.479

3.  Regulation of fibronectin-EDA through CTGF domain-specific interactions with TGFβ2 and its receptor TGFβRII.

Authors:  Rima Khankan; Noelynn Oliver; Shikun He; Stephen J Ryan; David R Hinton
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-07       Impact factor: 4.799

Review 4.  Fibronectins, their fibrillogenesis, and in vivo functions.

Authors:  Jean E Schwarzbauer; Douglas W DeSimone
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

5.  COX-2-derived prostaglandins as mediators of the deleterious effects of nicotine in chronic kidney disease.

Authors:  S Rangarajan; G Rezonzew; P Chumley; H Fatima; M Y Golovko; W Feng; P Hua; E A Jaimes
Journal:  Am J Physiol Renal Physiol       Date:  2019-12-16

6.  Targeting Anti-TGF-β Therapy to Fibrotic Kidneys with a Dual Specificity Antibody Approach.

Authors:  Steve McGaraughty; Rachel A Davis-Taber; Chang Z Zhu; Todd B Cole; Arthur L Nikkel; Meha Chhaya; Kelly J Doyle; Lauren M Olson; Gregory M Preston; Christine M Grinnell; Katherine M Salte; Anthony M Giamis; Yanping Luo; Victor Sun; Andrew D Goodearl; Murali Gopalakrishnan; Susan E Lacy
Journal:  J Am Soc Nephrol       Date:  2017-08-21       Impact factor: 10.121

7.  The p53 inhibitor pifithrin-α can stimulate fibrosis in a rat model of ischemic acute kidney injury.

Authors:  Pierre C Dagher; Erik M Mai; Takashi Hato; So-Young Lee; Melissa D Anderson; Stephanie C Karozos; Henry E Mang; Nicole L Knipe; Zoya Plotkin; Timothy A Sutton
Journal:  Am J Physiol Renal Physiol       Date:  2011-11-02

8.  Evidence for a differential expression of fibronectin splice forms ED-A and ED-B in Crohn's disease (CD) mucosa.

Authors:  Julia Brenmoehl; Markus Lang; Martin Hausmann; Sandra N Leeb; Werner Falk; Jürgen Schölmerich; Michael Göke; Gerhard Rogler
Journal:  Int J Colorectal Dis       Date:  2006-11-30       Impact factor: 2.571

9.  Differences between the early and advanced stages of rheumatoid arthritis in the expression of EDA-containing fibronectin.

Authors:  Magdalena Przybysz; Krzysztof Borysewicz; Iwona Katnik-Prastowska
Journal:  Rheumatol Int       Date:  2009-02-11       Impact factor: 2.631

10.  Cellular fibronectin expression in human trabecular meshwork and induction by transforming growth factor-β2.

Authors:  Wanda E Medina-Ortiz; Ricardo Belmares; Sandra Neubauer; Robert J Wordinger; Abbot F Clark
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-17       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.